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The clinical outcome of 52 consecutive patients with hyper-
trophic cardiomyopathy who developed paroxysmal « 1
week) or established (?:1 week) atrial fibrillation between
1960 and 1985 was examined retrospectively and compared
with that of a matched group of patients with hypertrophic
cardiomyopathy and sinus rhythm. Follow-up study until
death or the present ranged from 6 months to 24 years
(median 11 years) from diagnosis and from 6 months
to 22 years (median 7 years) from the onset of atrial
fibrillation. Atrial fibrillation was present in 6 patients
at the time of diagnosis, whereas it developed subsequently
in 46. The acute onset of arrhythmia was associated
with a change in symptoms in 41 (89%) of the 46. After
initial treatment of acute atrial fibrillation, sinus rhythm
was restored in 29 (63%) of the 46 patients; 43 (93%) of the
46 returned to their original symptom class. Stepwise
logistic regression revealed that shorter duration of ar-
rhythmia and amiodarone therapy were the most powerful
predictors of return to sinus rhythm. Sinus rhythm was
maintained during a median follow-up period of 5.5 years
Atrial fibrillation develops in approximately 15% of patients
with hypertrophic cardiomyopathy (1,2). It is associated
with functional deterioration and embolic complications and
is believed to herald a poor prognosis (3-6). To define the
natural history of this complication, we retrospectively
examined the presentation, treatment and outcome of 52
patients with hypertrophic cardiomyopathy who developed
atrial fibrillation.
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in 22 of the 29 patients in whom it was restored after initial
therapy.
During follow-up study, 25 of the 52 patients were
treated with conventional therapy alone and 7 with amio-
darone alone. Amiodarone therapy was associated with
maintenance of sinus rhythm, fewer alterations in drug
therapy, fewer embolic episodes and fewer attempted direct
current cardioversions (during a shorter follow-up period).
The remaining 20 patients initially received conventional
therapy but were not well controlled and were switched to
amiodarone (median 200 mg/day), after which there were
fewer alterations in drug therapy and fewer direct current
cardioversions during a similar follow-up period.
There were 19 disease-related deaths. Estimated prob-
ability of surviving 5, 10, 15 and 20 years after the diagnosis
of hypertrophic cardiomyopathy was 0.86, 0.71, 0.65 and
0.50 and was similar in a concurrent group of 122 patients
with hypertrophic cardiomyopathy who remained in sinus
rhythm (0.92, 0.82, 0.71 and 0.41), respectively.
(J Am Coli CardioI1990,'15:1279-85)
Methods
Study patients. Retrospective analysis of patients with
hypertrophic cardiomyopathy who were seen at Hammer-
smith Hospital between 1957 and 1985 revealed 52 who had
atrial fibrillation documented on physical examination and
rest or ambulatory electrocardiography (ECG), or both.
Atrial fibrillation was established (that is, duration?: 1week)
in 36 and paroxysmal (that is, duration> 1min and <1week)
in 16. Ambulatory ECG monitoring was available since 1978
and was performed at the time of diagnosis and at least
annually thereafter. In five patients, all with paroxysmal
episodes, atrial fibrillation was documented only during
ambulatory ECG monitoring. Clinical details including
symptoms, heart rate and rhythm, pharmacologic and elec-
trical therapy and complications were examined before and
after the acute onset of arrhythmia, after initial treatment
once stable maintenance therapy was achieved and during
0735-1097/90/$3.50
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Table 1. Clinical and Prognostic Features at Diagnosis in
52 Patients With Hypertrophic Cardiomyopathy and Atrial
Fibrillation and 122 Patients With Hypertrophic
Cardiomyopathy and Sinus Rhythm
Atrial Sinus
Fibrillation Rhythm
(n = 52) (n = 122)
Age at diagnosis (yr)
<21 6 (12) 35 (29)
>21 46 (88) 87 (71)
Year of diagnosis
1958-1969 15 (29) 34 (28)
1970-1979 32 (61) 66 (54)
1980-1985 5 (10) 22 (18)
Gender (male/female ratio) 1.26 1.25
Family history of HCM and sudden death 10 (19) 20 (16)
NYHA functional class at diagnosis
I 17 (33) 53 (44)
II 22 (42) 59 (48)
III/IV 13 (25) 10 (8)
Syncope 7 (13) 32 (26)
Ventricular tachycardia on 48 h ECG
Detected* 7 (13) 25 (20)
Unknownt 17 (33) 42 (34)
Not detected 28 (54) 55 (46)
*Twenty-three of 25 patients in sinus rhythm and all 7 in atrial fibrillation
who had ventricular tachycardia detected received low dose amiodarone;
tpatients evaluated before 1978. Numbers in parentheses indicate percent.
ECG =electrocardiogram; HCM = hypertrophic cardiomyopathy; NYHA =
New York Heart Association.
long-term follow-up study. All surviving patients were re-
viewed between January and July 1986. Survival was com-
pared with that in 122 patients with hypertrophic cardiomy-
opathy and sinus rhythm who were matched for age,
duration and follow-up study from diagnosis and risk factors
for sudden death and cardiac death (Table 1).
Clinical features. Of the 52 patients with atrial fibrillation,
29 were male and 23 female. They were aged 6 to 72 years
(median 47) at the time of diagnosis of hypertrophic cardio-
myopathy. Before the onset of atrial fibrillation, 22 (42%)
had dyspnea (New York Heart Association functional class
II, III or IV), 17 (33%) had exertional chest pain, 7 (14%) had
experienced syncope and an additional 6 (12%) presyncope.
Diagnosis was based on the demonstration of typical clinical
and angiographic features (7) and, after 1980, the echocar-
diographic demonstration of unexplained left ventricular
hypertrophy (8). Fifty of the 52 patients underwent left and
right heart catheterization at diagnosis. Mean right atrial
pressure was 4 to 14 mm Hg (mean 8). Pulmonary capillary
wedge and left ventricular end-diastolic pressures were 7 to
35 mm Hg (mean 20) and 7 to 32 mm Hg (mean 21),
respectively. A left ventricular outflow tract gradient of ::::30
mm Hg was recorded at rest in 25 patients (48%) and could
be provoked in a further 8 patients. Twenty-seven (52%) of
50 patients had angiographic evidence of mitral regurgita-
tion, which was graded as mild in 18, moderate in 7 and
severe in 2 (9).
Twenty-six patients underwent conventional M-mode or
two-dimensional echocardiographic examination, or both
(10,11). In 10 patients studied 1 month to 4 years (median 7
months) before the onset of arrhythmia, M-mode echocar-
diography revealed left atrial dimensions of 30 to 50 mm
(mean 43) and septal thickness of 15 to 40 mm (median 23).
Left ventricular dimensions at end-systole and end-diastole
were 20 to 40 mm (mean 31) and 32 to 50 mm (mean 41),
respectively. In 16 who were examined 7 months to 22 years
(median 4 years) after the appearance of atrial fibrillation,
left atrial dimension was 35 to 69 mm (mean 49), maximal
septal thickness was 15 to 35 mm (mean 20) and left
ventricular dimensions were 22 to 40 mm (mean 33) and 32 to
52 mm (mean 44) at end-systole and end-diastole, respec-
tively.
In 24 patients, technetium-99m equilibrium radionuclide
cineangiography (12,13) was performed within 2 years be-
fore arrhythmia (n = 2) or during periods of sinus rhythm
(range 1month to 14 years, median 5 years after the onset of
arrhythmia, n = 21). Mean ejection fraction was 71 ± 14%.
Mean peak ejection rate and time to peak ejection were 3.2
± 0.8 end-diastolic volume·s- I and 182 ± 5 ms, respectively.
Peak filling rate and time from Rwave to peak filling were 3.1
± 0.8 end-diastolic volume·s-I and 506 ± 125 ms, respec-
tively.
Treatment. Before 1980, atrial fibrillation was managed
with conventional drugs, including digoxin, verapamil or a
beta-adrenergic blocking agent combined with a class I
antiarrhythmic agent (either quinidine or disopyramide)
where necessary. After 1980, low dose amiodarone was used
in 8 of 12 patients with recent onset atrial fibrillation and in
those in whom chronic established or paroxysmal atrial
fibrillation was refractory to conventional medical therapy
(14,15). Selection criteria for initial therapy with amiodarone
or conventional drugs reflected individual physician prefer-
ences; the two patient groups (amiodarone versus conven-
tional treatment) were similar in age, gender, maximal left
ventricular wall thickness and characteristics of atrial fibril-
lation. Patients received an oral loading dose of amiodarone
(600 to 1,200 mg/day for 1week), followed by a maintenance
dose of 100 to 400 mg/day (median 200) adjusted to achieve
control of arrhythmia with plasma amiodarone concentra-
tions <1.5 mg/liter (14). All patients with either paroxysmal
or established atrial fibrillation received coumarin anticoag-
ulant therapy. The indications for the use of direct current
cardioversion as an adjunct to pharmacologic treatment for
acute and chronic atrial fibrillation differed according to
physician preferences. All patients with established atrial
fibrillation in whom pharmacologic cardioversion was unsuc-
cessful underwent at least one attempt at direct current
cardioversion.
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Figure 1. New York Heart Association functional class in patients
in sinus rhythm before the development of atrial fibrillation (left),
during acute atrial fibrillation (AF) (center) and after initial therapy
(right). bpm = beats/min; HR = heart rate.
Statistical analysis. Student's t test was used for compar-
ison of mean values of normally distributed data. The
Mann-Whitney test was used for unpaired ordinal data.
Fisher's exact test was used for nominal data. The Wilcoxon
rank sum test was used for comparison of paired ranked
data. Multiple logistic regression analysis was used to deter-
mine significant differences in groups of variables, where
appropriate. Survival in patients with atrial fibrillation was
compared with that in a concurrent group of patients with
hypertrophic cardiomyopathy and sinus rhythm using the
log-rank test and two-tailed p values. The effect of other risk
factors on the interpretation of these results was examined
using the proportional hazards model. Kaplan-Meier esti-
mates were calculated for the probability of surviving 5, 10,
15 and 20 years after diagnosis. Computer analyses were
performed using the SAS statistical package.
Dyspnea
class
II
III
IV
Sinus
rhythm
Aller initial
127±24 75±10
Results
Paroxysmal versus established atrial fibrillation. Estab-
lished atrial fibrillation was present at diagnosis in 6 patients
and developed in an additional 30 patients I month to 18
years (median 2 years) after diagnosis. Prior episodes of
paroxysmal atrial fibrillation were recorded in 14 of the 30
patients, whereas in 16 patients established atrial fibrillation
had not previously occurred. Ambulatory ECG monitoring
was performed in a similar proportion of patients with and
without documented paroxysmal episodes preceding the
development of established atrial fibrillation. The remaining
16 patients who were followed up for 6 months to 13 years
(median 4.3 years) after diagnosis had paroxysmal episodes
without developing established atrial fibrillation. More of
these latter patients received amiodarone (p < 0.05) and
fewer were in functional class III or IV (p < 0.05), but they
were similar with respect to age, left ventricular septal
thickness, incidence and severity of left ventricular gradient
and left ventricular end-diastolic pressure compared with the
14 patients with paroxysmal atrial fibrillation who developed
established atrial fibrillation.
Initial Episode of Paroxysmal and Established
Atrial Fibrillation
Symptoms. During the acute onset of atrial fibrillation,
seven patients had new or more severe chest pain, five had
presyncope and one had syncope. The clinical status of all
patients in functional class III and of the majority in class I
and II deteriorated by at least one functional class (Fig. 1).
The 12 patients in class I or II whose status did not
deteriorate were similar in age, left ventricular end-diastolic
dimension, maximal wall thickness and ventricular response
during atrial fibrillation to the 34 whose status did deterio-
rate, and a similar proportion were taking atrioventricular
(AV) node blocking drugs (8 of 12 versus 18 of 34, respec-
tively). Radionuclide measurements were available in 5 of
the 12 patients who remained in the same symptom class
after the acute onset of atrial fibrillation. They had a higher
ejection fraction (84 ± 6.2% versus 64 ± 13%, p < 0.02),
peak ejection rate (4.0 ± 0.6 versus 2.9 ± 0.4 end-diastolic
volume's- I , p < 0.02) and peak filling rate (3.4 ± 0.7 versus
2.9 ± 0.8 end-diastolic volume's- I , p < 0.08) than the five
patients whose status deteriorated after the acute onset of
atrial fibrillation who were matched for age, gender and
symptom class before atrial fibrillation.
After initial therapy for atrial fibrillation, sinus rhythm
returned in 29 patients and persisted in 17. All patients with
reversion to sinus rhythm and 14 of the 17 who remained in
atrial fibrillation were restored to their original functional
class.
Therapy. Details of initial therapy were available in the
46 patients who developed paroxysmal or established atrial
fibrillation after diagnosis; 38 received conventional treat-
ment, 7 received amiodarone and 1 had both treatments. Of
those treated conventionally, 22 (58%) of 38 returned to
sinus rhythm and 16 (42%) remained in atrial fibrillation,
whereas 7 (87%) of 8 who received amiodarone returned to
sinus rhythm. Initial treatment included attempted direct
current cardioversion in 20 patients; 8 of 16 patients who
received conventional therapy, 2 of 3 who took amiodarone
and 1 patient who had both conventional therapy and amio-
darone reverted to sinus rhythm. Of the 26 patients in whom
cardioversion was not attempted, sinus rhythm returned in
14 of 22 on conventional therapy and 4 of 4 treated with
amiodarone. Return to sinus rhythm was associated with
less severe functional class during arrhythmia (p < 0.01),
duration of arrhythmia <1 week (that is, paroxysmal fibril-
lation [p < 0.01]) and amiodarone therapy (p < 0.05).
Stepwise logistic regression analysis revealed that duration
of atrial fibrillation <1 week (p < 0.005) and amiodarone
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Figure 3. Outcome of 36 patients with established atrial fibrillation
(AF) in relation to treatment. Fourteen of the 36 patients had
experienced documented paroxysmal atrial fibrillation (see Fig. 2).
Conventional therapy = open circles; amiodarone = hatched circles;
abbreviations as in Figure 2.
Figure 4. Treatment requirements, attempted direct current cardio-
versions and embolic complications in 25 patients receiving conven-
tional therapy (top) and 7 who initially received amiodarone (bot·
tom). The 20 patients who failed conventional therapy and who were
switched to amiodarone are shown in the center. D.C. = direct
current.
AFAFSRAFSR
Treatment Median D.C. shock Drug Total embolic
follow-up per patient regimes episodes
(years) per patient
Conventional 8.0 1.1 2.0 9
(n=25)
Conventional 3.8 1.1 2.5 2
(n=20)
+Amiodarone 5.3 0.1 1.1 0
Amiodarone 4.0 0.1 1.1 0
(n~7)
fibrillation with improved control of the ventricular re-
sponse. Of these 36 patients with established atrial fibrilla-
tion, 3 required a demand pacemaker for conduction system
disease associated with conventional therapy (n = 2) or
amiodarone (n = 1).
In total, 45 of the 52 patients received conventional
therapy either alone (n = 25) or followed by amiodarone
(n = 20) (Fig. 4 and 5). The remaining seven patients
received amiodarone alone; they had a shorter follow-up
period (median 4 versus 8 years), fewer drug regimens (mean
1.1 per patient on amiodarone versus 2 per patient on
conventional therapy, p < 0.05) and fewer embolic episodes
(0 versus 9, respectively, p < 0.01). During a matched
follow-up period of 3.5 years, sinus rhythm was maintained
in 6 (87%) of 7 patients receiving amiodarone compared with
5 (11 %) of 45 patients who received conventional treatment
only (p < 0.01).
After a follow-up period of6 months to 22 years (median
5.5 years), the 45 patients who received conventional ther-
apy required a total of 98 drug regimens (mean 2.25 ± 1.8)
Conventional Rx
PAF
l
PAF
PAF
SR
therapy (p < 0.03) were the most powerful predictors of
return to sinus rhythm.
Thromboembolism. The onset of atrial fibrillation was
associated with thromboembolic episodes in two patients;
one had multiple systemic emboli and the other had a
pulmonary embolus. Two other patients had systemic
thromboemboli I and 3 years, respectively, before the doc-
umented onset of atrial fibrillation.
Long-Term Follow-Up
Symptoms. During long-term follow-up study (median 7
years), 2 (13%) of 16 patients with paroxysmal and 5 (14%) of
36 with established atrial fibrillation showed a decline of one
or more functional class.
Therapy. Of 30 patients with documented paroxysmal
atrial fibrillation, 4 received amiodarone and 26 had conven-
tional therapy (Fig. 2). All four patients who received
amiodarone had remained in sinus rhythm. Of the 26 patients
on conventional therapy, 14 developed established atrial
fibrillation, 5 maintained sinus rhythm and 7 continued to
have symptomatic episodes of paroxysmal atrial fibrillation.
In the latter seven patients, treatment was changed to
amiodarone and six remained asymptomatic in sinus rhythm.
Of 36 patients with established atrial fibrillation (includ-
ing 14 with prior episodes ofparoxysmal atrial fibrillation) 6
received amiodarone and 30 had conventional therapy
(Fig. 3). Sinus rhythm was restored in four of the six on
amiodarone therapy and atrial fibrillation persisted in two.
Of those who received conventional therapy, all continued
to have established atrial fibrillation, with a controlled ven-
tricular response in 20 patients and poor control (mean
heart rate at rest >90 beats/min) in 10. These 10 patients
were switched from conventional therapy to amiodarone; 4
had reversion to sinus rhythm and 6 remained in atrial
Figure 2. Outcome of 30 patients with paroxysmal atrial fibrillation
(PAF) in relation to treatment (Rx). *Patient had exacerbation of
paroxysmal atrial fibrillationlflutter on amiodarone and was returned
to conventional therapy. Conventional therapy = open circles;
amiodarone = hatched circles; EAF = established atrial fibrillation,
SR = sinus rhythm.
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onset of atrial fibrillation. In the remaining three patients, the
development of atrial fibrillation and the embolic event
preceded diagnosis. Systemic emboli lodged in the brain
(n = 6), limbs (n = 2), gut (n = I) and left coronary artery
(n = I); cerebral embolism was fatal in two of the six
patients. All but 1patient had established atrial fibrillation; 2
were in functional class I, 4 in class II, 3 in class III or IV,
and 4 of the 10 were on anticoagulant therapy at the time
embolism occurred.
Survival. There were 22 deaths: 6 sudden, 6from cardiac
failure, 2 after myocardial infarction, 3 perioperatively after
cardiac myotomy/myectomy, 2 from a cerebrovascular ac-
cident and 3 from noncardiac causes (Fig. 5). Cumulative
survival figures for all patients from the time of diagnosis of
established or paroxysmal atrial fibrillation were 85%, 70%
and 62% at 5, 10 and 15 years, respectively. At 5 years, the
mortality rate for paroxysmal and established atrial fibrilla-
tion was similar (15% versus 10%, p = NS); the number of
patients with paroxysmal atrial fibrillation and long-term
follow-up were too few for comparison after 5 years.
The 52 patients with atria/fibrillation were compared with
a concurrent group of122 patients with hypertrophic cardio-
myopathy and sinus rhythm to see if this arrhythmia affected
survival. The presence of known risk factors (nonsustained
ventricular tachycardia, syncope, functional class III or IV,
family history of sudden death and diagnosis of hypertrophic
cardiomyopathy at a young age) were taken into account in
making the comparison. Table 1 compares the two groups
for presence of risk factors, gender and calendar year of
diagnosis. Estimated probability of survival was similar in
patients with atrial fibrillation and sinus rhythm (Fig. 6,
Table 2; log-rank test p = 0.5). None of 6 patients with atrial
fibrillation aged ::;21 years at diagnosis died compared with
Figure 6. Probability of survival for 52 patients with hypertrophic
cardiomyopathy and atrial fibrillation and 122 concurrent patients
with hypertrophic cardiomyopathy who remained in sinus rhythm.
The difference is not significant.
Figure 5. Cause of death in 52 patients with hypertrophic cardio-
myopathy and atrial fibrillation in relation to treatment. See text for
discussion. Conventional therapy = open circles; amiodarone =
hatched circles; CCF = congestive heart failure; MI = myocardial
infarction; post op. = after cardiac surgery.
and 49 direct current cardioversion attempts (mean 1.1 ±
1.8) (Fig. 4). The 20 whose treatment was changed to
amiodarone were analyzed separately; during a follow-up
period of 3 months to 12 years (median 4 years) on conven-
tional therapy, they had 50 drug regimens (mean 2.5) and 22
cardioversion attempts (mean l.l). After the change to
amiodarone, they had fewer alterations of therapy (20 versus
50 regimens, p < 0.001) and fewer cardioversion attempts (2
versus 20, p < 0.006) despite a longer follow-up period (2
months to 7.3 years, median 5.3 years).
Side effects. During conventional therapy (median 5.5
years), side effects that required alteration of treatment
developed in 14 (31%) of 45 patients, During amiodarone
therapy (median 4.9 years), unwanted side effects (photosen-
sitivity, sleep disturbance, tremor, gastrointestinal) were
seen in 16 (59%) of 27 patients; of these, 3 required alterna-
tive therapy.
Predictors of arrhythmia. The 17 patients with atrial
fibrillation after initial therapy continued to have it during
the long-term follow-up period of 1to 22 years (median 8). Of
29 patients with sinus rhythm after initial therapy, 22 re-
mained in sinus rhythm and 7 had recurrence of atrial
fibrillation. Univariate analysis revealed that less severe
functional impairment during initial arrhythmia (p < 0.01)
and shorter follow-up from the development of paroxysmal
or established atrial fibrillation (6 months to 13 years [median
5.5 years] versus 2.2 months to 17.8 years [median 9 years],
p < 0.05) were associated with the maintenance of sinus
rhythm. Stepwise logistic regression analysis indicated that
shorter duration of follow-up was the most powerful predic-
tor of maintenance of sinus rhythm (p < 0.02).
Thromboembolic events. During the follow-up period,
embolism occurred in 10 male patients. Two patients had
two separate embolic events and five had a single embolic
episode 3 months to 8 years (median 1.5 years) after the
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Patients with sinus rhythm
(n = 122)
Patients with atrial fibrillation
(n = 52)
5
0.92 (0.03)*
(n = 95)
0.86 (0.05)*
(n = 44)
10
0.82 (0.04)*
(n = 59)
0.71 (0.07)*
(n = 29)
15
0.71 (0.06)*
(n = 21)
0.65 (0.07)*
(n = 18)
20
0.41 (0.14)*
(n = 4)
0.50 (0.09)*
(n = 7)
*Standard error of probability of survival.
11 (31%) of35 of similar age at diagnosis who did not develop
atrial fibrillation. In those >21 years at diagnosis, 22 (48%) of
46 patients with atrial fibrillation died versus 17 (20%) of 87
patients with sinus rhythm (p = 0.1 I).
Discussion
Atrial fibrillation is common in hypertrophic cardiomyop-
athy. Data from referral centers (1,2,7,16) suggest that
approximately 5% of patients have established atrial fibril-
lation at the time ofdiagnosis, and an additional I0% develop
the arrhythmia during the next 5 years. Published reports on
the outcome of patients with hypertrophic cardiomyopathy
who develop atrial fibrillation are sparse. Invasive hemody-
namic studies before and after direct current cardioversion
and isolated reports (3,17) indicate that the acute onset of
atrial fibrillation is poorly tolerated and potentially fatal. A
poor prognosis has been assumed, though this is not con-
firmed by existing natural history studies (5,16).
Clinical effect of atrial fibrillation. In this study, the
functional class in 34 (74%) of the 46 patients deteriorated
after the onset of atrial fibrillation. In 12 patients (26%),
however, the acute onset of atrial fibrillation was well
tolerated; their mean heart rate was 120 beats/min. reflecting
the prior administration of an AV node blocking drug;
relative control of the ventricular response may have pre-
vented serious deterioration. The finding of an increased
ejection fraction and peak ejection and filling rate in patients
whose status did not deteriorate also suggests that left
ventricular function is potentially an important determinant
of the symptomatic response to atrial fibrillation in hyper-
trophic cardiomyopathy. After initial therapy and either
restoration of sinus rhythm or control of the ventricular
response, 43 (93%) of 46 patients were returned to their
original functional class, including 14 of the 17 who remained
in atrial fibrillation. Thus, the loss of atrial systole was well
tolerated and appeared to be less important than the hemo-
dynamic consequences of a poorly controlled ventricular
response.
After the initial documented episode ofatrialfibrillation,
29 (63%) of 46 patients had a return to sinus rhythm with
pharmacologic therapy alone (n = 18) or with additional
cardioversion (n = I I). Return to sinus rhythm was best
predicted by a shorter duration of arrhythmia and treatment
with amiodarone. In patients with established atrial fibrilla-
tion, restoration and maintenance of sinus rhythm was less
common; 28 of the 36 patients remained in atrial fibrillation
over the long term (Fig. 3).
Clinical effect of amiodarone versus conventional therapy.
During long-term follow-up study, patients who received
amiodarone required fewer alterations in drug therapy, had
fewer embolic episodes and significantly more (6 of7 versus
5 of 45, p < 0.001) remained in sinus rhythm for >3 years
after the initial episode of atrial fibrillation compared with
those who received conventional therapy. In those with
previously unsuccessful conventional therapy, amiodarone
was associated with fewer cardioversion attempts during the
follow-up study, fewer changes in drug therapy and a lower
incidence of the development of established atrial fibrilla-
tion. Unwanted effects often limit the use of amiodarone,
particularly when administered in daily doses of 2:400 mg
(18-20). In this study, the median daily dose of amiodarone
was 200 mg and no patient received more than 400 mg/day:
16 (59%) of 27 patients developed side effects, but in the
majority, these were minor and only 3 patients (10%) re-
quired alternative therapy. On conventional therapy, side
effects that required a change in treatment developed in 14
(31 %) of 45 patients. These uncontrolled data suggest a
beneficial effect of low dose amiodarone in the day-to-day
management of atrial fibrillation, but this warrants confirma-
tion in a controlled study.
Survival. The annual mortality rate in patients with hy-
pertrophic cardiomyopathy is approximately 2% to 4%, and
the majority die suddenly (16,21-23). The development of
atrial fibrillation is thought to be a poor prognostic sign. In
this study, the 5 year mortality rate was only 14%, and the
majority of patients did not die suddenly. Nineteen of the 52
patients died from a disease-related cause, including 6 with
cardiac failure, 3 perioperatively after myectomy, 2 from a
cerebrovascular accident and 2 from myocardial infarction.
These deaths were in patients>21 years of age; none of the
six younger patients died. The 5 year survival rate was
similar in patients with paroxysmal and established atrial
fibrillation and in those who remained in sinus rhythm.
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Limitations. Alimitation ofthis retrospective study is the
fact that clinical, ECG and Holter assessments were per-
formed during routine clinical follow-up study over a 20 year
period and not according to a fixed protocol. In particular,
this may have influenced patient selection in relation to
choice of therapy, and there is the potential for a sampling
error in the assessment of paroxysmal atrial fibrillation in
relation to the development of established atrial fibrillation.
The decisions to use amiodarone and cardioversion were
determined by physician preference and were not guided by
a previously established protocol. The fact that clinical
features were similar in the groups who received amiodarone
and conventional treatment does not, however, suggest an
important selection bias.
Conclusions. Atrial fibrillation does not represent an om-
inous development in the natural history of patients with
hypertrophic cardiomyopathy. After the development of
acute atrial fibrillation, symptoms are common and are
related not only to control of the ventricular response, but
also to impairment of left ventricular systolic and diastolic
function. Most patients can not only be returned to their
original functional class, but many are also restored to sinus
rhythm. In the long term, amiodarone may be successful in
preventing the progression of paroxysmal to established
atrial fibrillation and may facilitate management in doses that
are not associated with significant side effects. Long-term
survival is common and, overall, patients who develop atrial
fibrillation do not appear to have a worse prognosis than do
those who remain in sinus rhythm.
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